FeesSafety
Pluang+

GE Aerospace upgraded to Buy after strong Q3 results and raised 2026 guidance

Analyst Insights
23 Oct 2026
Seeking Alpha
View Source
Bullish
GE Aerospace upgraded to Buy after strong Q3 results and raised 2026 guidance

GE Aerospace received a Buy upgrade following strong Q3 performance, including non-GAAP EPS of $2.25 and 18% revenue growth. Management also raised full-year 2026 guidance across key metrics, boosting investor confidence. The stock shows nearly 10% upside potential to a $324 target with technical support near $270. Risks remain from supply chain challenges, inflation, and market cyclicality, but the company's exposure to defense and AI infrastructure supports its positive outlook.

GE Aerospace's recent upgrade and Q3 results provide context for readers; here is Pluang's Industrials sector snapshot as of Oct 23, 2026 14:51 WIB: Among 135 priced US Industrials stocks, 73 rose and 56 fell today. Notable moves include TRI (Thomson Reuters Corp) at USD 123.26 with a 6.94% gain and a typical hold time of 64 days, SMX (SMX Security Matters plc) down 6.56% to USD 1.71 with a 52% sell order activity and 22 days typical hold time, and IR (Ingersoll Rand) at USD 73.89, down 6.53%, with a 12-day typical hold time.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
17 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App